Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations.

This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised.

A companion website includes the fully searchable text and an image bank.

Section 1: BASIC PRINCIPLES OF CANCER TREATMENT

1: Clinical Strategies for Cancer Treatment: The Role of Drugs

Bruce Chabner

2: Target Identification and Drug Discovery

Ed Sausville

3: Clinical Drug Development and Approval for Marketing

Thomas Roberts

4: Principles of Pharmacokinetics

Jerry Collins

5: Special Aspects of Brain Tumor Chemotherapy

Jeffrey Supko & Tracy Batchelor

6: Pharmacogenetics

Howard McLeod

7: Barriers to Drug Delivery

Brendan Curti

Section 2: CYTOTOXIC AGENTS

8: Antifolates

Carmen Allegra & Bruce Chabner

9: Fluoro-pyrimidines

David Ryan, Bruce Chabner & Ray Wadlow

10: Cytidine Analogues

David Ryan & Bruce Chabner

11: Purine Analogues

Ken Hande

12: Hydroxyurea

Bruce Chabner

13: Antimitotic Drugs

Ross Donehower

14: Alkylating Agents (Including Methylating Agents)

Stan Gerson & Henry Friedman

15: Platinum Analogues

Ed Reed

16: Antitumor Antibiotics (Including Bleomycin)

Bruce Chabner

17: Topoisomerase I Inhibitors

Alex Spaareboom & William Zamboni

18: Topoisomerase II Inhibitors: Anthracyclines

Jim Doroshow

19: Topoisomerase II Inhibitors: Etoposide, Teniposide

George Hartman & Yves Pommier

20: L-Asparaginase

Bruce Chabner & Alison Friedmann

Section 3: MOLECULARLY TARGETED THERAPIES

21: Proteosome Inhibitors

Orhan Sezar

22: HDAC Inhibitors

Susan Bates

23: Differentiating Agents (Retinoids)

Bruce Chabner

24: Arsenic Trioxide

Bruce Chabner

25: Monoclonal Antibodies: Discovery & Development

David Scheinberg

26: Anti-angiogenic Agents (Including MonAB)

William Gradishar & Kari Wisinski

27: Anti-EGFR Therapies (Including MonAB)

Lecia Sequist & Joel Neal

28: Anti-her 2 Therapies

Eric Winer

29: Intracellular Signal Inhibitors (bcr-abl)

Bruce Chabner & Jeffrey Barnes

30: Signal Transduction Inhibitors in Development

Jeff Clark

31: Inhibitors of the PI3k Pathway & Mitotic Kinase

Percy Ivy

Section 4: IMMUNOLOGIC AGENTS

32: Interferon and Cytokines

David McDermott

33: Vaccines

Robert G. Fenton

34: Adoptive Cellular Therapies

Cassian Yee

35: Immuno-modulatory Drugs (IMIDS, Anti-CTLA4)

Paul Richardson et al.

Section 5: HORMONAL THERAPY

36: Hormonal Therapy of Breast Cancer

Beverly Moy & Paul Goss

37: GNRH Agonists and Anti-Androgens

Richard Lee

Section 6: SUPPORTIVE CARE

38: Pain Management in Cancer Patients

Paul Glare

39: Colony Stimulating Factors

Gary Lyman

40: Anti-nausea Medications

Ian Olver

41: Bone Loss Modulators

Matthew Smith

42: Intravenous Access and Catheter Management

Rachel Rosovsky

Section 7: SURVIVORSHIP

43: Monitoring for Late Side Effects of Chemotherapy

Richard Schilsky, Charles Erlichman & Brian Costello